„This is a randomised, phase III, non-inferiority trial evaluating radiation therapy (RT) versus observation (no RT) following breast conserving surgery in patients who are planned to receive adjuvant endocrine therapy for stage I breast cancer of luminal A subtype and Risk of Recurrence (ROR) score ≤60 characterised using Prosigna (PAM50) Assay.”